
SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD
Description
About SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD
The SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) Nucleoprotein Peptide (IEDB: 1310488) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Nucleoprotein Peptide, H-IGYYRRATRRIRGGD-OH (Uniprot: P0DTC9 aa: 84-98) from JPT is produced under strict quality control and quality management.
SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD - Specifications
- Peptide sequence: H-IGYYRRATRRIRGGD-OH
- Amount: 10 mg (10 x 1 mg)
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Covid-19
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD
References:
Read References with JPT’s Antigen Peptides
SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD has been described in:
SARS-CoV-2-derived peptides define heterologous and COVID-19-induced T cell recognition., Nat Immunol, 2021 (PMID: 32999467)
T cell and antibody kinetics delineate SARS-CoV-2 peptides mediating long-term immune responses in COVID-19 convalescent individuals., Sci Transl Med, 2021 (PMID: 33723016)
Documentation
Documentation for SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD
Properties
Properties of SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Covid-19 |
Layout: | Freeze-dried in glass vial |
Organism: | SARS-CoV-2 (Severe Acute Respiratory Syndrome-related coronavirus 2) |
Protein Name: | Nucleoprotein |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to SARS-CoV-2 Nucleoprotein 84-98, IGYYRRATRRIRGGD
Information | Values |
---|---|
Sequence: | H-IGYYRRATRRIRGGD-OH |
Specifications: | 15mer peptide as TFA salt |